Navigating medical device biocompatibility evaluations can often feel like solving a maze blindfolded, especially when trying to reconcile shifting global standards with FDA expectations. Fortunately, the FDA recently hosted the final installment of its comprehensive three-part town hall series, bringing together regulatory experts to demystify toxicological risk assessments (TRAs). Drawing from updated consensus standards like ISO 10993-17 and ISO/TS 21726, the panel offered much-needed clarity on extractables, thresholds, and margin of safety calculations. Whether you are an industry veteran or steering early-stage life science innovations, understanding these nuances is critical for streamlining your path to market. Here are five key observations from the session that can help sharpen your next regulatory submission.
First, while the updated 2023 edition of ISO 10993-17 brings welcome modernization to the TRA process, the FDA does not recognize it entirely. Specifically, Table E.2 and certain text snippets regarding extraction surface areas conflict with the agency’s biocompatibility guidance, meaning sponsors must align their worst-case exposure calculations with FDA expectations rather than blindly following every clause in the standard. Second, reporting extractable quantities simply in micrograms per device is frequently insufficient. The agency emphasized that toxicologists must calculate a true maximum total quantity (TQmax) and worst-case estimated per day exposure dose (EEDmax) based on actual clinical use scenarios, such as the simultaneous or sequential use of multiple devices. Third, to help bring consistency to these complex evaluations, CDRH’s Office of Science and Engineering Laboratories has rolled out a web-based Regulatory Science Tool known as the TEEM Calculator. This tool automates the application of Toxicological Screening Limits (TSLs) and EEDmax formulas to derive Margins of Safety (MoS), though human subject matter experts must still validate all underlying data inputs. Fourth, if your calculated MoS falls below 1.0, it does not immediately mean your device is unsafe. The agency outlined a clear roadmap for these scenarios, urging sponsors to conduct rigorous root cause analyses, apply practical risk mitigation, or leverage established benefit-risk frameworks when necessary. Finally, a recurring pitfall in submitted TRA reports is the total absence of an explanation regarding why a chemical screening study method is adequate. Including a clear statement in your regulatory package detailing the representativeness of your extraction conditions, whether via targeted release kinetics or non-targeted screening, prevents unnecessary deficiency letters.
Mastering the intricacies of toxicological risk assessments requires a careful balance of rigorous science, standard compliance, and proactive agency engagement. By leveraging modern tools like the TEEM Calculator and maintaining transparent justifications for your chemical analyses, your team can avoid common compliance pitfalls. Ultimately, aligning early with the FDA’s least-burdensome philosophy ensures that safety evaluations serve their true purpose: protecting patients while accelerating life-saving innovations to the clinic. You can read the full Town Hall meeting transcript here.
